Back to top

Image: Bigstock

Humana Inc. (HUM) Hit a 52 Week High, Can the Run Continue?

Read MoreHide Full Article

A strong stock as of late has been Humana (HUM - Free Report) . Shares have been marching higher, with the stock up 11.2% over the past month. The stock hit a new 52-week high of $462.87 in the previous session. Humana has gained 80.1% since the start of the year compared to the 9% gain for the Zacks Medical sector and the 28.6% return for the Zacks Medical - HMOs industry.

What's Driving the Outperformance?

The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on November 6, 2026, Humana reported EPS of -$0.7 versus consensus estimate of -$1.03.

For the current fiscal year, Humana is expected to post earnings of $9.48 per share on $161.68 in revenues. This represents a -44.69% change in EPS on a 24.57% change in revenues. For the next fiscal year, the company is expected to earn $17.2 per share on $170.9 in revenues. This represents a year-over-year change of 81.46% and 5.7%, respectively.

Valuation Metrics

Humana may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.

On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.

Humana has a Value Score of B. The stock's Growth and Momentum Scores are B and B, respectively, giving the company a VGM Score of A.

In terms of its value breakdown, the stock currently trades at 48.7X current fiscal year EPS estimates, which is a premium to the peer industry average of 20.7X. On a trailing cash flow basis, the stock currently trades at 19.2X versus its peer group's average of 17.7X. Additionally, the stock has a PEG ratio of 2.24. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks Rank

We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Humana currently has a Zacks Rank of #1 (Strong Buy) thanks to favorable earnings estimate revisions from covering analysts.

Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Humana meets the list of requirements. Thus, it seems as though Humana shares could have a bit more room to run in the near term.

How Does HUM Stack Up to the Competition?

Shares of HUM have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is UnitedHealth Group Incorporated (UNH - Free Report) . UNH has a Zacks Rank of #2 (Buy) and a Value Score of A, a Growth Score of B, and a Momentum Score of F.

Earnings were strong last quarter. UnitedHealth Group Incorporated beat our consensus estimate by 13.83%, and for the current fiscal year, UNH is expected to post earnings of $23.38 per share on revenue of $449.12 billion.

Shares of UnitedHealth Group Incorporated have gained 1.3% over the past month, and currently trade at a forward P/E of 19.99X and a P/CF of 19.38X.

The Medical - HMOs industry is in the top 13% of all the industries we have in our universe, so it looks like there are some nice tailwinds for HUM and UNH, even beyond their own solid fundamental situation.

Published in